Predictive biomarkers for responsiveness to FOLFOX in gastric cancers based on integrative profiling of patient-derived xenografts

Gastric cancer (GC) is the second leading cause of cancer-associated death worldwide. Curative surgery followed by systemic chemotherapy containing 5-fluorouracil (5-FU) derivatives and platinum combination chemotherapy is the standard of care for GC patients. However, there is a lack of the clinically applicable predictors of FOLFOX (folinic acid, 5-FU and oxaliplatin) combination chemotherapy. Herein, we developed patient-derived xenograft (PDX) models from 31 GC patients treated with combination of 5-FU and oxaliplatin to provide predictive biomarkers for drug responsiveness based on extensive genomic and transcriptomic characterization of chemotherapy responsiveness of tumors.